Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
目的：认识儿童非霍奇金淋巴瘤(NHL)及白血病肾脏浸润的各种CT表现。
Purpose: To understand the various CT findings of renal involvement of non-Hodgkin lymphoma (NHL) and leukemia in children.
目的了解多中心协作化疗方案(MCP方案)对急性淋巴细胞白血病(all)和非霍奇金淋巴瘤(NHL)患儿肾脏功能的影响。
Objective to investigate the renal damages in children with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) who received the intensive multicenter-protocols (MCP).
它对血细胞的毒性作用已得到很好地记载，而且已知它导致不同类型的白血病、多发性骨髓瘤和非霍奇金淋巴瘤。
Its toxic effects on blood cells are well documented and it's known to cause different kinds of leukaemia, multiple myeloma and non-Hodgkin lymphoma.
它对血细胞的毒性作用已得到很好地记载，而且已知它导致不同类型的白血病、多发性骨髓瘤和非霍奇金淋巴瘤。
Its toxic effects on blood cells are well documented and it's known to cause different kinds of leukaemia, multiple myeloma and non-Hodgkin lymphoma.
应用推荐